In this regard, a radiolabeled monoclonal antibody targeting CD147 was evaluated in a randomized, phase 2, clinical trial in hepatocellular carcinoma patients and found that targeting CD147 doubled tumor control (43% vs. 22%) [60]. The gene discussed is BSG; the disease is hepatocellular carcinoma.